University of Texas: Intratumoral Heterogeneity May Be Responsible for Chemotherapy Resistance in Patients With Small Cell Lung Cancer
February 18, 2020
February 18, 2020
HOUSTON, Texas, Feb. 18 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release on Feb. 17:
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leadi . . .
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leadi . . .